糖尿病与他汀的纠葛,这8大要点你必须掌握!

2019-04-16 郭艺芳 郭艺芳心前沿

糖尿病患者服用他汀要注意些什么?甲减患者要注意哪些?他汀会增高血糖吗?肝功能轻中度异常能用他汀治疗吗?打消疑惑,这8大要点助你掌握!

糖尿病患者服用他汀要注意些什么?甲减患者要注意哪些?他汀会增高血糖吗?肝功能轻中度异常能用他汀治疗吗?打消疑惑,这8大要点助你掌握!

经常有人问:哪些糖尿病患者需要吃他汀?

简单的回答是:

1)所有合并冠心病或脑梗死,或颈动脉、下肢动脉狭窄超过50%的患者均应该服用他汀;

2)所有40岁以上的糖尿病人都应该服用他汀。

笔者认为,糖尿病对人类健康最大的危害是引起心绞痛、心梗、脑梗等动脉粥样硬化性血管疾病。积极有效的降低血液胆固醇水平是预防糖尿病合并血管疾病的关键措施。

那么,他汀需要服用多长时间?老年糖尿病患者服用他汀要注意些什么?甲减患者要注意哪些?他汀会增高血糖吗?肝功能轻中度异常能用他汀治疗吗?你是否也有这些疑问呢?本文整理了内分泌科医师临床应用他汀的8个常见问题的解答。

1.哪些糖尿病人需要使用他汀治疗呢?

如果患者已经发生冠心病、甚至心梗、脑梗、严重颈动脉或下肢狭窄等病,无论血液胆固醇水平高不高,都应该立即开始他汀治疗。

如果没有发生上述疾病,糖尿病人发生心脑血管疾病的而风险也很高。若糖尿病人的年龄40岁以上且低密度脂蛋白胆固醇(LDL-C)达到1.8mmol/L或更高水平、或总胆固醇达到3.1mmol/L或更高水平,属于发生心脑血管疾病的高风险人群,应该应用他汀治疗,降低胆固醇水平。胆固醇是形成斑块的原料,血液中胆固醇水平越低,就越不容易形成动脉斑块,于是发生心脑血管疾病的而风险就会显着降低。

2.为什么说他汀是最重要的降胆固醇药物?

目前我国临床常用的调脂药物主要包括他汀类、贝特类、烟酸类以及胆固醇吸收抑制剂。其中他汀类药物具有最充分的随机临床研究证据,可以显着改善患者预后。

研究显示,低密度脂蛋白胆固醇(LDL-C)降低1 mmol/L,第1年内心梗、脑梗与心血管死亡风险降低约10%,2年后降低约16%,3年后降低约20%,此后治疗每延长1年,这些严重事件风险进一步降低1.5%,治疗5年后风险降低20%~25%。

贝特类与烟酸类药物一直广泛应用于临床。近年来多项随机临床研究发现,贝特类与烟酸类药物虽可对血脂谱产生有益影响,却未能显着减少主要心血管终点事件与全因死亡率。

因此,不推荐首选这两类药物用于血脂异常药物干预,除非患者甘油三酯(TG)严重升高或患者不能耐受他汀治疗。当患者经过强化生活方式干预以及他汀类药物充分治疗后TG仍不达标时(>2.3 mmol/L),可考虑在他汀治疗基础上加用非诺贝特或烟酸缓释剂。

3.他汀需要吃多长时间?

服用他汀后胆固醇会明显降低,这种情况下应该继续服药,不能停药。因为停药后胆固醇会重新升高,心脏或脑血管的粥样斑块将会继续加重。只要没有明显副作用,绝大多数人需要长期吃下去,不能擅自停药。

实际上,多数糖尿病及其心血管并发症如高血压、冠心病等都需要终身服药,因为目前尚没有根治这些疾病的办法。有些虚假广告声称能够根治糖尿病等,这是骗人的,不能相信。

4.老年人使用他汀的注意事项有哪些?

高龄老人中甲状腺功能减退患病率很高,此类患者对于他汀的耐受性更差,因此应用他汀前应注意检查甲状腺功能,必要时予以药物治疗。

高龄老年患者较少发生严重的高胆固醇血症,其主要原因是饮食摄入胆固醇量减少、肝脏合成胆固醇能力减弱,并存慢性消耗性疾病的患者尤为如此。因而多数患者经过较低剂量的他汀治疗即可使血脂达标。

要考虑到患者肝肾功能状态、并存其他疾病情况、合并用药情况、以及患者的预期寿命。由于许多老年患者常常应用多种药物,因此需要充分重视药物之间的相互作用。例如老年心血管病患者常用的维拉帕米、胺碘酮等可增加他汀不良反应的风险,必要时应更换药物、减小剂量并加强监测。

与此同时,应根据患者具体病情全面评估治疗方案,优先保证疗效确切、且能够改善预后的药物,而停用或缓用那些疗效不确切或仅能改善症状的药物。

大量饮酒与饮用大量西柚汁也可能增加他汀不良反应风险,需尽量避免。

严重感染、创伤或接受大型手术治疗期间对他汀的耐受性更差,必要时应考虑减量。

他汀的种类与剂量的选择需要个体化,从小剂量开始用药,在监测肝肾功能和肌酸激酶的前提下合理调整药物用量。在出现肌肉无力、肌肉疼痛、肌肉酸软、肌肉僵直、运动时或运动不久后肌肉痉挛等症状时需及时就诊,并及时复查血清肌酸激酶水平,与老年性骨、关节和肌肉疾病鉴别。

由于现有的大规模临床试验中较少包括80岁以上的高龄老年患者,其降脂疗效与安全性尚需更多的循证医学证据。因此,对于这一人群应采取较为谨慎的干预策略:既要对所存在的血脂异常进行干预,又不提倡使用大剂量他汀类药物。同时,在治疗过程中应加强不良反应监测,对于特别是体重较轻的女性患者尤应如此。

5.他汀治疗会增高血糖吗?

是的。现有研究显示,长期应用他汀类药物治疗可能会增加新发糖尿病风险。应用大剂量他汀治疗时对糖代谢的影响进一步增加。这种不良反应是他汀类药物的类效应,与应用何种他汀无直接关系。

需要指出的是,对于确诊冠心病、脑卒中和外周动脉疾病的患者以及具有多种心血管病危险因素者,应用他汀治疗的获益是肯定的,其降低心血管事件发生率、改善远期预后的有益作用远超过因增加糖代谢异常所致的不利影响,因而不应因为过度担忧这一不良反应而影响他汀类药物的合理应用。

在临床上,无论是糖尿病高危人群还是已经确诊糖尿病的患者,只要具备他汀治疗的适应证就一定要积极应用。对于这些患者,更应加强生活方式干预,特别是要嘱患者加强饮食控制与合理运动并控制体重,以降低新发糖尿病风险。若他汀治疗过程中出现血糖增高,可对其进行相应的非药物或药物治疗。

6.怕他汀有副作用,用其他药物降脂行不行?

不行,除非确认有严重不良反应而不能继续使用他汀治疗。虽然目前临床应用的降脂药还有很多种,但其疗效均不如他汀可靠。客观的讲,目前没有任何药物能够代替他汀。

少数人应用他汀治疗后的确可以出现某些副作用,例如肝功能异常、肌肉疼痛等,但绝大多数情况下这些副作用都比较轻微,在医生指导下都能够解决。只有极少数人不能耐受他汀治疗。

7.肝功能轻中度异常能用他汀治疗吗?

对于转氨酶轻中度异常的患者,临床医生往往拒绝为其应用他汀治疗。这种做法是不尽合理的。对于肝功能异常的患者,应鉴别其具体病因。若是由活动性肝炎等严重肝病所致的转氨酶升高,不应启动他汀治疗。

但在临床上,引起转氨酶轻中度升高的最常见原因是非酒精性脂肪肝(即除外酒精和其他明确因素所致的肝细胞内脂肪过度沉积),此类患者应用他汀治疗不仅安全有效,还能改善肝脏功能。

根据国内外相关指南,不伴有肝脏损害其他证据的单纯性轻中度转氨酶升高(其中绝大多数属于非酒精性脂肪肝)并非应用他汀的禁忌证。

相反,由于非酒精性脂肪肝与动脉粥样硬化性心血管疾病具有许多共同的病理生理机制,如胰岛素抵抗、氧化应激反应、脂代谢紊乱和脂质过氧化等,应用他汀治疗不仅不会加重肝脏损害,反而具有潜在治疗作用。

在临床实践中,从安全的角度上来说,不应将转氨酶轻中度升高作为拒绝使用他汀的依据。若患者没有肝肿大、黄疸、直接胆红素升高和(或)凝血酶原时间延长等器质性肝损害证据,应积极充分地使用他汀治疗。此类患者在他汀治疗过程中应加强监测,在服药4~8周后复查转氨酶水平,只要后者无进行性升高(≥3倍正常上限),则应继续用药。

8.应用他汀治疗时如何规避肌肉不良反应?

概括的讲,高龄、女性、体形瘦小、亚裔这4类患者在接受他汀治疗时发生肌肉不良反应的风险增高,这在日常临床工作应引起注意。由于遗传学背景不同,我国人群对于他汀的耐受性较差,这一点在2013年美国成人降胆固醇治疗指南中也有述及。

HPS2- THRIVE研究(共纳入25673例受试者,其中我国患者10932例)表明,在同等剂量他汀治疗时,我国患者发生肌病的风险是欧洲患者的10倍。因此,在确定他汀治疗剂量时,必须充分考虑到我国与欧美人种的差异,而不应盲从他国指南。

在并存其他疾病时,患者对于他汀的耐受性也可能降低,进而增加肌肉不良反应的风险。例如急性感染、甲状腺功能减退、严重肝肾功能减退、严重创伤等应激状态、糖尿病、接受大型手术等患者,应用他汀治疗时也应加强监测,必要时减小剂量甚至暂停用药。其中甲状腺功能减退最值得关注。我国人群,特别是中年患者中,临床型或亚临床型甲状腺功能减退较为常见,由于不重视该病的筛查,很多患者不能得到及时诊断。对于准备启动他汀治疗的患者,应该将甲状腺功能检查作为必要的评估项目之一。确诊甲状腺功能减退者应首先进行治疗,纠正甲状腺功能后再启动他汀治疗。

药物之间相互作用是另一个值得关注的问题。多种常用药物会对他汀的药代动力学状态产生影响,如钙拮抗剂、卡维地洛、格列奈类、胺碘酮、普罗帕酮、酮康唑、氟康唑、红霉素和吉非罗奇等。在应用他汀时,应尽量避免合并使用上述药物,必须合用时应评估是否需要调整他汀的种类或剂量。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2020-03-02 jyzxjiangqin

    糖尿病患者的治疗新进展。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2020-02-18 jyzxjiangqin

    糖尿病患者的治疗。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2020-02-05 jyzxjiangqin

    糖尿病患者的治疗。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2020-01-01 jyzxjiangqin

    糖尿病患者的治疗。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-12-16 jyzxjiangqin

    糖尿病患者的治疗。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-12-06 jyzxjiangqin

    糖尿病患者的治疗。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-11-25 jyzxjiangqin

    糖尿病患者的治疗。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-11-11 jyzxjiangqin

    糖尿病患者的治疗。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-10-28 jyzxjiangqin

    糖尿病患者的治疗。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=380000, encodeId=1f72380000a5, content=糖尿病患者的治疗新进展。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Mar 02 18:06:33 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379383, encodeId=036d3e938325, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Feb 18 18:33:52 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378937, encodeId=4db83e893758, content=糖尿病患者的治疗。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 05 18:03:17 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377669, encodeId=b7e13e7669f2, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 01 16:39:08 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377037, encodeId=5bea3e70374c, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 16 19:20:56 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376636, encodeId=38173e663672, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Dec 06 19:38:20 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375820, encodeId=54023e5820eb, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 25 20:06:55 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375052, encodeId=0e473e5052bd, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Nov 11 20:08:41 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374531, encodeId=6cc53e45316f, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Oct 28 20:07:57 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374051, encodeId=95683e4051aa, content=糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Oct 17 20:05:49 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-10-17 jyzxjiangqin

    糖尿病患者的治疗。

    0

相关资讯

Lancet:Meta分析:≥75岁老年人吃他汀也可获益

据Lancet上发表的一项Meta分析,无论年龄大小,他汀类药物都能减少主要血管事件,包括75岁以上的老年人。

JAHA:他汀类药物依从性降低的心梗患者死亡风险**

许多急性心梗(AMI)后的老年患者在他汀类药物的依从性方面有所变化,但其与死亡率的相关性尚不清楚。本研究纳入了101011名2008-2010年年龄≥66岁的AMI住院患者,并对患者AMI前180天和AMI后180天的他汀类药物依从性进行了评估,分为非常不依从、轻中度不依从和依从三类。经过平均18个月时间的随访,20%的患者依从性明显提高,16%有所降低,14%患者无论AMI前还是AMI后均为不依

Brit J Clin Pharmacol:他汀增加糖尿病风险获新证,胖人和HbA1c高者应警惕

既往不少研究发现,他汀会升高糖尿病风险。近期发表的一项来自荷兰的前瞻性人群研究再次证实了这一点,且超重、肥胖和糖尿病前期人群应用他汀时风险尤其高。

JAHA:拒绝或中断他汀药物治疗的原因调查研究

许多应接受他汀类药物治疗的心血管疾病患者没有接受他汀治疗,本研究的目的旨在探究患者自述的未接受他汀药物治疗的原因。本研究纳入了PALM数据库中的5693名推荐接受他汀药物治疗的患者。调查结果发现,有1511名(26.5%)患者未接受他汀药物治疗,其中894名(59.2%)患者自述未提供他汀药物,153名(10.1%)患者主动拒绝他汀药物治疗,464名(30.7%)患者中断了他汀药物治疗。女性、黑种

Curr Pharm Des:他汀类药物在非酒精性脂肪性肝病治疗中的作用

在线发表于《Curr Pharm Des》杂志上的一项综述指出,非酒精性脂肪性肝病(NAFLD)及其晚期非酒精性脂肪性肝炎(NASH)患者有较高的CVD风险,服用他汀类药物和普通人群一样安全,可以选择一种特定的他汀类药物(阿托伐他汀)来显著减少肝脏和CVD相关的不良事件。

"肝功能异常"能否使用他汀?

对于转氨酶轻中度异常的患者,临床医生往往拒绝为其应用他汀治疗。这种做法是不尽合理的。对于肝功能异常的患者,应鉴别其具体病因。若是由活动性肝炎等严重肝病所致的转氨酶升高,不应启动他汀治疗。